CL2022002093A1 - Anticuerpos para usar en terapia. - Google Patents

Anticuerpos para usar en terapia.

Info

Publication number
CL2022002093A1
CL2022002093A1 CL2022002093A CL2022002093A CL2022002093A1 CL 2022002093 A1 CL2022002093 A1 CL 2022002093A1 CL 2022002093 A CL2022002093 A CL 2022002093A CL 2022002093 A CL2022002093 A CL 2022002093A CL 2022002093 A1 CL2022002093 A1 CL 2022002093A1
Authority
CL
Chile
Prior art keywords
antibodies
therapy
binds
human
binding agent
Prior art date
Application number
CL2022002093A
Other languages
English (en)
Inventor
Ugur Sahin
Alexander Muik
Isil Altintas
Ulf Forssmann
Kate Sasser
Maria N Jure-Kunkel
Manish Gupta
Original Assignee
Genmab As
BioNTech SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As, BioNTech SE filed Critical Genmab As
Publication of CL2022002093A1 publication Critical patent/CL2022002093A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se relaciona con un método para reducir o prevenir la progresión de un tumor o para tratar un cáncer. El método comprende administrar a un sujeto un agente de unión que comprende una primera región de unión que se une al CD137 humano y una segunda región de unión que se une al PD-L1 humano. La cantidad de agente de unión que se administra en cada ciclo de tratamiento es preferiblemente entre aproximadamente 0,3 y 5 mg/kg de peso corporal o entre aproximadamente 25 y 400 mg en total.
CL2022002093A 2020-02-04 2022-08-03 Anticuerpos para usar en terapia. CL2022002093A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062970046P 2020-02-04 2020-02-04
US202063027702P 2020-05-20 2020-05-20
US202063110633P 2020-11-06 2020-11-06

Publications (1)

Publication Number Publication Date
CL2022002093A1 true CL2022002093A1 (es) 2023-02-10

Family

ID=74586991

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002093A CL2022002093A1 (es) 2020-02-04 2022-08-03 Anticuerpos para usar en terapia.

Country Status (12)

Country Link
US (1) US20230087164A1 (es)
EP (1) EP4100059A1 (es)
JP (1) JP2023513896A (es)
KR (1) KR20220137054A (es)
CN (1) CN115135344A (es)
AU (1) AU2021215332A1 (es)
BR (1) BR112022015151A2 (es)
CA (1) CA3169963A1 (es)
CL (1) CL2022002093A1 (es)
IL (1) IL294967A (es)
MX (1) MX2022009091A (es)
WO (1) WO2021156326A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117603360A (zh) * 2020-12-16 2024-02-27 美勒斯公司 用于治疗癌症的多特异性抗体
CA3233512A1 (en) 2021-10-06 2023-04-13 Alexander Muik Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
IL311771A (en) 2021-10-06 2024-05-01 BioNTech SE Multispecific binding agents against PD-L1 and CD137 in combination
WO2023146394A1 (en) * 2022-01-25 2023-08-03 Merus N.V. Combination therapy for the treatment of cancer
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
CN103097417B (zh) 2010-04-20 2019-04-09 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
JP6726656B2 (ja) 2014-04-01 2020-07-22 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｃｅｌｌ ＆ Ｇｅｎｅ Ｔｈｅｒａｐｉｅｓ Ｇｍｂｈ クローディン６特異的免疫受容体およびｔ細胞エピトープ
JP6744326B2 (ja) 2015-01-08 2020-08-19 バイオエヌテック エスエーＢｉｏｎｔｅｃｈ Ｓｅ アゴニスト性ｔｎｆ受容体結合物質
JP7022993B2 (ja) * 2016-01-11 2022-02-21 インヒブルクス インコーポレイテッド 多価かつ多重特異性の４１ｂｂ結合融合タンパク質
NZ751956A (en) * 2016-09-23 2022-01-28 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
CA3071211A1 (en) 2017-08-04 2019-02-07 Genmab A/S Binding agents binding to pd-l1 and cd137 and use thereof
US20220049007A1 (en) * 2018-07-12 2022-02-17 F-Star Beta Limited Antibody molecules that bind pd-l1 and cd137
AU2019375014A1 (en) * 2018-11-06 2021-05-27 BioNTech SE Antibody formulation

Also Published As

Publication number Publication date
CN115135344A (zh) 2022-09-30
KR20220137054A (ko) 2022-10-11
MX2022009091A (es) 2022-09-19
US20230087164A1 (en) 2023-03-23
WO2021156326A1 (en) 2021-08-12
AU2021215332A1 (en) 2022-08-18
CA3169963A1 (en) 2021-08-12
IL294967A (en) 2022-09-01
BR112022015151A2 (pt) 2022-12-20
JP2023513896A (ja) 2023-04-04
EP4100059A1 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
CL2022002093A1 (es) Anticuerpos para usar en terapia.
Lindegaard et al. Has the outlook improved for amifostine as a clinical radioprotector?
BR0209147A (pt) Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais
CL2021002267A1 (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t. (divisional de solicitud 202002945)
Schild et al. Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unresectable non–small-cell lung cancer
EA201650134A1 (ru) Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором
MX336710B (es) Oligoribonucleotidos y metodos de uso de los mismos para tratamiento de la alopecia, insuficiencia renal aguda y otras enfermedades.
RU2012140447A (ru) Антиангиогенная терапия для лечения рака яичника
AR074203A1 (es) Terapia anti-angiogenesis para el tratamiento del cancer de mama. kit. uso.
MX2019013701A (es) Metodos para mejorar suministro de farmacos y efectividad de agentes terapeuticos.
BRPI0816317A2 (pt) Método para tratar o estresse oxidativo e melhorar a memória de trabalho pela administração de pterostilbeno
Bartelink et al. The combined use of radiotherapy and chemotherapy in the treatment of solid tumours
JP2020117553A5 (es)
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
Hehr et al. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial
MX2022012351A (es) Administracion conjunta de mirdametinib y lifirafenib para uso en el tratamiento de canceres.
AR049135A1 (es) Composicion,metodo, kit y tratamiento con oxaliplatino y un inhibidor del egfr,como erlotinib
MX2022014223A (es) Terapia de combinacion para amiloidosis de la ttr.
DE60331827D1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
MX2021014103A (es) Compuestos de briostatina para mejorar la inmunoterapia.
EA202191165A1 (ru) Элацестрант в комбинации с абемациклибом у женщин с раком молочной железы
MX2023006404A (es) Terapia combinada de anticuerpos y taxanos.
MX2024001892A (es) Una combinacion terapeutica que comprende un antagonista de tigit, un antagonista de pd-1 y uno o varios agentes quimioterapeuticos.
EA200501456A1 (ru) Торий- 227 для применения в радиотерапии заболевания мягких тканей
MX2022011171A (es) Compuestos con actividad inmunomodulatoria y usos terapeuticos de estos.